Because our work helps make global health responses more efficient, more effective and – most importantly – ensures people in low- and middle-income countries have access to the highest quality health products out there.
Because our work helps make global health responses more efficient, more effective and – most importantly – ensures people in low- and middle-income countries have access to the highest quality health products out there.
This is according to an independent modelling exercise, commissioned to understand the overall health and economic impact of our investments in innovative health products. Looking at sixteen key products across four disease areas – HIV, tuberculosis, malaria and hepatitis C – the analysis estimated the value of our contribution to scaling up access to these products in low- and middle-income countries. The analysis found that for every US$1 invested in health innovations, US$46 are saved.
Importantly, we don’t only invest in products with the highest financial return. Many of the innovations we support are designed to reach communities that markets often overlook—such as children, pregnant women, or people in remote or underserved settings. These products may be more costly to scale, or their benefits harder to quantify in purely economic terms. But they are essential to building fairer, more inclusive health systems—and to ensuring that no one is left behind.
Download the technical appendix, for more information.
We take a close look at global disease responses to understand why certain medicines, tests and other health products may not be reaching everywhere they are needed and where new interventions could help fill gaps. Then we tackle the barriers that restrict access – often working across several parts of the problem at the same time – so high-quality care can reach as widely as possible.
Access to innovation is at the heart of our work. Find out more about the critical global health tools and strategies we support.